Company Overview
YiChenBio is an innovative biotech enterprise expanding the engineered protein therapeutic boundaries, focusing on cancer, autoimmune diseases, pain management, and metabolic disorders. The company’s founder and key management team members are from Novartis, Merck, and other well-known institutions.
YiChenBio has established innovative antibody, bispecific antibody, and long-acting protein therapeutic platforms. These novel technologies and molecular designs aim to solve the key issues in the field and facilitate the development of engineered protein therapeutics for a variety of indications. YiChenBio is currently advancing more than 20 pre-clinical programs, of which 3 are expected to file IND applications by 2026.
Business Development
YiChenBio has completed Angel- and Series A-funding and is advancing a focused portfolio of pre-clinical programs, with six programs in IND enabling studies.
YiChenBio is actively seeking opportunities to leverage its proprietary technologies (bispecific antibody platforms, Bs-ADC and LATP) to co-develop therapeutic products outside of YiChenBio’s pipeline with partners. YiChenBio also evaluates partnership opportunities with biopharmaceutical companies possessing complementary capabilities.
Our Team
Feng Wang, Ph.D
Founder, CEO
Huayang Zheng
COO
James Schaeffer, Ph.D
Business development VP
Yan Liu, Ph.D
Director of R&D
Suxin Zheng, Ph.D
Director of Pharmacology
